Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

59
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
59
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.7K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.7K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

327
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
327
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

2.3K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.3K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.8K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Downed woody debris carbon emissions in a European temperate virgin forest as driven by species, decay classes, diameter and microclimate.

The Science of the total environment·2023
Same author

Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015.

BMC public health·2022
Same author

Prisons: an important link in the elimination of Hepatitis B.

Revista espanola de sanidad penitenciaria·2022
Same author

Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2020
Same author

Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015.

BMC public health·2020
Same author

Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2018
Same journal

Monitoring of the Cascade of Care in Patients With Chronic HBV in Primary Care Clinics in Australia.

Journal of viral hepatitis·2026
Same journal

HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis D.

Journal of viral hepatitis·2026
Same journal

Assessing the Utility of Shortened Read Time of the Abbott Bioline HCV Test to Predict Viremia.

Journal of viral hepatitis·2026
Same journal

Cardiac MRI Identifies Subclinical Myocardial Tissue Abnormalities in Individuals With Hepatitis C Regardless of Myocardial Damage Markers or Fibrosis Stage.

Journal of viral hepatitis·2026
Same journal

Drug Use and Social Connectivity Related to Hepatitis C Infection Among Rural People Who Use Drugs.

Journal of viral hepatitis·2026
Same journal

Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United States.

Journal of viral hepatitis·2026
See all related articles

Related Experiment Video

Updated: Apr 12, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Therapy for hepatitis C genotype 3: moving forward.

M Buti1,2, J Llaneras1, M Riveiro-Barciela1

  • 1Liver Unit, Internal Medicine Department, Vall d'Hebron Hospital, Barcelona, Spain.

Journal of Viral Hepatitis
|May 14, 2015
PubMed
Summary
This summary is machine-generated.

Sofosbuvir plus ribavirin offers effective hepatitis C virus genotype 3 treatment for most patients. However, lower sustained virologic response rates occur in experienced patients with cirrhosis, necessitating new therapeutic strategies.

Keywords:
daclatasvirdirect-acting antiviralgenotype 3hepatitis Csofosbuvirtreatment

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.9K

Related Experiment Videos

Last Updated: Apr 12, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.9K

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) genotype 3 treatment evolved from interferon-based regimens.
  • Direct-acting antivirals (DAAs) have transformed HCV therapy, with sofosbuvir-based regimens now standard.
  • Challenges remain in achieving high sustained virologic response (SVR) in specific patient populations.

Purpose of the Study:

  • To review current treatment standards for HCV genotype 3.
  • To evaluate the efficacy of sofosbuvir-based regimens in different patient groups.
  • To identify unmet needs and future directions for HCV genotype 3 treatment, particularly in treatment-experienced patients with cirrhosis.

Main Methods:

  • Review of current clinical guidelines and published literature on HCV genotype 3 treatment.
  • Analysis of treatment outcomes for sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir regimens.
  • Discussion of treatment challenges and emerging therapeutic strategies.

Main Results:

  • Sofosbuvir plus weight-based ribavirin for 24 weeks demonstrates high SVR rates in treatment-naïve and non-cirrhotic patients.
  • Lower SVR rates are observed with sofosbuvir plus ribavirin in treatment-experienced patients with cirrhosis.
  • A 12-week regimen of sofosbuvir and daclatasvir also shows limited efficacy in this difficult-to-treat population.

Conclusions:

  • Current DAA regimens are highly effective for most HCV genotype 3 patients.
  • Treatment-experienced patients with cirrhosis represent a population requiring novel therapeutic approaches.
  • High drug costs remain a significant barrier to widespread HCV treatment access globally.